Point-of-care prenatal testing in resource-limited settings — the deployment of rapid diagnostic tests, portable ultrasound, and simplified screening tools enabling antenatal care quality improvement in low- and middle-income countries where laboratory infrastructure, specialist availability, and healthcare facility proximity limitations create the highest global burden of preventable maternal and neonatal mortality — representing the global health and access dimension of the Prenatal Testing And Newborn Screening Market, with point-of-care prenatal diagnostics potentially preventing hundreds of thousands of preventable deaths annually through earlier detection of pregnancy complications.

Maternal syphilis screening — the eliminating congenital syphilis imperative — WHO's Global Health Sector Strategy targeting elimination of mother-to-child transmission (EMTCT) of HIV and syphilis requiring near-universal antenatal syphilis screening and treatment, with point-of-care rapid syphilis tests enabling screening during antenatal visits in facilities without laboratory send-out capability. SD BIOLINE Syphilis 3.0, Determine Syphilis TP (Abbott), and similar rapid treponemal and dual HIV/syphilis point-of-care tests enabling same-visit screening and treatment initiation — preventing congenital syphilis (stillbirth, neonatal death, multi-organ disease in infected newborns) through treatment of maternal infection with benzathine penicillin G that is nearly one hundred percent effective in preventing vertical transmission when administered adequately during pregnancy.

Portable ultrasound democratization — the POCUS obstetric revolution — the dramatic cost reduction and capability improvement in portable handheld ultrasound (Butterfly iQ+, Philips Lumify, GE Vscan Air, Clarius) enabling basic obstetric ultrasound capability in remote health centers, mobile health clinics, and community health worker programs previously without any imaging. Basic obstetric POCUS enabling: confirmation of intrauterine pregnancy (versus ectopic), fetal viability assessment, gestational age estimation (improving dating accuracy for preterm birth management), placenta previa identification, fetal presentation determination (enabling planned delivery mode for malpresentation), and multiple gestation identification — collectively providing the clinical information that enables appropriate obstetric management in resource-limited settings where specialist ultrasound was previously inaccessible.

Newborn screening in LMICs — the access gap challenge — the profound disparity in newborn screening coverage between high-income countries (near-universal coverage for twenty-plus conditions) and low-income countries (limited or no systematic newborn screening for most conditions) representing one of healthcare's most glaring equity gaps. Phenylketonuria (PKU) — a condition causing severe intellectual disability preventable by early dietary treatment — untreated in the majority of affected children in sub-Saharan Africa, South Asia, and other low-income regions due to absent newborn screening programs. WHO and March of Dimes initiatives supporting newborn screening program development in LMICs through dried blood spot screening technology transfer, quality assurance program development, and pilot program funding — with PKU and congenital hypothyroidism as the initial priority conditions for newborn screening expansion in low-resource settings.

Do you think international health investment priorities will shift sufficiently to establish functional newborn screening programs in low-income countries within the next decade, or will the combination of healthcare infrastructure gaps, laboratory supply chain challenges, and competing health investment priorities maintain the current profound newborn screening equity gap?

FAQ

What point-of-care tests are available for antenatal screening in resource-limited settings? POC antenatal testing for LMICs: syphilis: SD BIOLINE Syphilis 3.0 (Abbott) — rapid treponemal test; fingerstick blood; fifteen minutes; sensitivity >97%; Determine Syphilis TP — treponemal; widely distributed through PEPFAR and Global Fund; dual HIV/syphilis: Determine HIV-1/2 Ag/Ab + Determine Syphilis TP combo; or single dual tests; enabling same-visit screening and treatment; HIV: rapid HIV antibody tests; WHO-prequalified rapid tests; enabling same-visit PMTCT (prevention of mother-to-child transmission); nevirapine or ART initiation; malaria: malaria RDTs (HRP-2 based); pregnant women highly susceptible to severe malaria; symptomatic and asymptomatic testing; blood group and Rh factor: point-of-care blood typing cards; ABO and Rh typing at antenatal visit; identifying Rh-negative mothers for anti-D prophylaxis; anemia: HemoCue Hb 301 — hemoglobin from fingerstick; rapid anemia screening; guiding iron supplementation and referral; pre-eclampsia: urinary dipstick for proteinuria; blood pressure measurement; combined for pre-eclampsia screening; PlGF (placental growth factor) — POC tests emerging for pre-eclampsia risk (Quidel PIGF Plus, Roche Elecsys PlGF); limited availability in LMICs; gestational diabetes: glucometer-based glucose testing; one-hour fifty-gram glucose challenge alternative to laboratory OGTT; context-appropriate screening; hepatitis B: HBsAg rapid test; identifying mothers for neonatal birth dose hepatitis B vaccination; congenital rubella prevention: rubella IgG POC test; identifying susceptible women for post-partum vaccination; quality assurance: WHO prequalification of POC tests for LMIC use; PEPFAR, Global Fund, UNICEF procurement guidance; cold chain requirements (most RDTs 2–30°C storage — manageable without refrigeration in most settings).

What newborn hearing screening programs exist and how is universal hearing screening implemented? Newborn hearing screening global implementation: epidemiology: congenital hearing loss — one to three per one thousand live births; most common congenital sensory impairment; early identification before six months enabling language development with hearing aids or cochlear implantation; EHDI (Early Hearing Detection and Intervention): US mandate: JCIH (Joint Committee on Infant Hearing) recommending 1-3-6 model: screening by one month; diagnosis by three months; intervention by six months; RUSP-included: critical congenital hearing loss on RUSP (UNHS since 2010); technology: OAE (otoacoustic emissions): transient-evoked OAE or DPOAE; automated; ninety seconds per ear; sensitivity ninety-seven percent; specificity ninety-three percent; automated ABR (auditory brainstem response): neural pathway assessment; better for auditory neuropathy; used as second-tier screening or diagnostic; AABR (automated ABR): Natus Algo, Maico MB 11; ideal for NICU where OAE less reliable; two-stage screening: OAE first (NICU and well-baby nursery) → refer to AABR → refer to diagnostic ABR → audiologist; coverage: US UNHS: >98% of newborns screened; Europe: most EU countries with UNHS programs; LMICs: OAE-based programs feasible with portable equipment; limited by diagnostic follow-up capacity; genetic testing: GJB2 (connexin 26) gene mutations causing approximately fifty percent of autosomal recessive hearing loss; carrier testing for couples with family history; newborn genomic sequencing programs including GJB2 in hearing-related gene panels.

#NewbornHearingScreening #PrenatalTestingMarket #UniversalNewbornScreening #MaternalHealthLMIC #PointOfCarePrenatal